A High THC Dose Felt Like Psilocybin. The Study Had Four People
A Johns Hopkins pilot found that a high oral dose of THC felt, to its participants, a lot like psilocybin. The paper appeared in Psychopharmacology and moved fast through the psychedelic press, including Marijuana Moment. Before it travels further, the sample size deserves equal billing. Four people took part.
Patients arrive having read the headline, not the sample size. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The study | A blinded pilot from Johns Hopkins University School of Medicine, published September 2026 |
| Participants | Four adults, each completing three to four sessions |
| What they received | 25 mg psilocybin, 25 mg THC, 50 mg THC distillate, and placebo, all oral |
| The headline finding | At 25 mg, THC was rated as more like a classic psychedelic than like a cannabinoid |
| At the higher dose | 50 mg read as mostly sedative or dissociative, and only moderately psychedelic |
| Who funded it | The Wana Brand Foundation, which is affiliated with a cannabis company |
What the Study Did
Participants attended several blinded sessions. Neither they nor the session monitors knew which substance had been given.
There were four conditions. Psilocybin at 25 mg. THC at 25 mg, given as either synthetic dronabinol or whole plant distillate. THC distillate at 50 mg. And placebo. Everything was taken orally.
Afterward participants guessed what they had received, choosing between a classic psychedelic, a dissociative, a sedative, and a cannabinoid. That guessing task is the core measure.
The Finding Everyone Is Quoting
All four correctly identified placebo. That is a reasonable sign the blinding worked at the low end.
At 25 mg, both forms of THC were rated as more like a classic psychedelic than like a cannabinoid. The authors describe the experience as similar to 25 mg psilocybin.
The 50 mg distillate went a different direction. It read as predominantly sedative or dissociative, and only moderately psychedelic. More THC did not mean more psychedelic.
Four People Is the Whole Study
This is the part the headlines drop. The sample is four adults.
With four participants, a single person changing an answer moves any percentage by 25 points. There is no meaningful statistical power, and the authors present it as preliminary.
That does not make it worthless. Blinded within-subject designs can be informative at small scale, and this one was carefully constructed. It makes it a signal to test, not a fact to repeat.
Who Paid For It
Funding came from the Wana Brand Foundation, which is affiliated with a cannabis company.
This does not make the measurements wrong. Read the measurement and the interpretation separately, as always.
But a cannabis-funded study concluding that THC produces psilocybin-like experiences has an obvious commercial use. That context belongs next to the result.
What It Would Mean If It Held Up
The interesting implication is not that cannabis is secretly a psychedelic. It is that the subjective categories people use may be blunter than the pharmacology.
Much of psychedelic research leans on subjective report, including the mystical experience scales used to predict outcomes. If a high THC dose can be mistaken for psilocybin, those scales may be measuring intensity and strangeness rather than a drug class.
The field is already picking at questions like this, including the argument over what the therapy component of a psilocybin session actually is.
Why This Is Not a Green Light
Nothing here suggests cannabis belongs in a clinical protocol. The study measured what an experience felt like, not whether it treated anything.
There were no depression outcomes, no anxiety outcomes, and no follow up. Similarity of subjective experience is not evidence of similar therapeutic effect.
Real world data has also shown adverse effects surfacing well after a session, as Oregon’s program outcomes demonstrated. A four person pilot cannot see anything like that.
The Bottom Line
Treat this as a curiosity that earned its coverage on novelty rather than weight. It is a hypothesis with four data points and a cannabis foundation behind it.
What is worth watching is whether anyone replicates it at scale, with clinical outcomes and independent funding. Until then the honest description is narrow. Four people could not reliably tell a large THC dose from psilocybin. Our piece on session length as the real constraint covers how the field is thinking about dose more broadly.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical advice. Cannabis and psilocybin remain controlled substances under federal law. Nothing here describes an approved treatment.
